Skip to content
2000
Volume 11, Issue 7
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The powerful inducer of apoptosis Apo2L/TNF-related apoptosis-inducing ligand (TRAIL) has generated exciting promise as a potential tumour specific cancer therapeutic agent, since it selectively induces apoptosis in transformed versus normal cells. Interferons (IFNs) are important modulators of TRAIL expression, thus the ligand appears to play an important role in surveillance against viral infection and malignant transformation. In the light of the emerging importance of TRAIL in cancer therapy, we will discuss the molecular basis of the cooperation of TRAIL and IFNs or chemotherapeutic drugs. In particular, we will focus on the data known to date concerning the biochemical pathways leading to TRAIL-induced apoptosis in specific cancer cells and warranting further work to enable the investigation in cancer patients.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612053381729
2005-03-01
2025-05-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612053381729
Loading

  • Article Type:
    Review Article
Keyword(s): apoptosis; cancer therapy; chemotherapeutic drugs; ifns; trail
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test